$33 million in Series B investment was received by Atropos Health, a Palo Alto, California-based pioneer in converting real-world clinical data into high-quality individualized real-world evidence for therapy.
Investors
- Valtruis
- Breyer Capital
- Emerson Collective
- Presidio Ventures
- Cencora Ventures
- McKesson Ventures
- Merck GHI Fund
It collaborates with healthcare and life science institutions to reduce evidence gaps from bench to bedside, enhance patient outcomes via data-driven treatment, accelerate medical research, and more.
The company’s portfolio of evidence-generating apps, which Arcadia and other Atropos Health partners have long used, promotes value-based performance and whole-person care. Healthcare companies may expedite optimal clinical decision-making using the company, enabling them to provide patients with high-value, cost-effective treatment tailored to their individual physiology.
About Atropos Health
It was established in 2019 as a spin-out of the Stanford University “Green Button” technology, which was developed by Brigham Hyde, Ph.D., Nigam Shah, MBBS, Ph.D., and Saurabh Gombar, M.D., Ph.D. GENEVA OSTM is the operating system for rapid healthcare evidence across a network of real-world data.
